As of Apr 17
| -2.89 / -2.48%|
The 25 analysts offering 12-month price forecasts for Celgene have a median target of 143.00, with a high estimate of 163.00 and a low estimate of 83.00. The median estimate represents a +26.02% increase from the last price of 113.47.
The current consensus among 28 polled investment analysts is to Buy stock in Celgene. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.